All News

ACRmtg.jpg (keep)

EULAR 2024 – Day 3 Report

Jack Cush, MD

EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.

Read Article
computer screen safety

Impact of regulatory warning on JAK inhibitors

Md Yuzaiful Md Yusof, MRCP(UK), PhD

The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL surveillance clinical trial in 2022. Subsequently, both the FDA and EMA issued a warning on using JAKi in patients with certain risk factors, e.g., ≥65 years, at increased risk of MACE, current smoker or past smoker and at increased risk of cancer, should other alternative treatment be available. So, how has this warning impacted on JAKi development and use?

Read Article
Synovitis

Might Synovial Biopsy Predict Rheumatoid Treatment Responses?

EurekAlert!

Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy. 

Read Article
RA Hands Difficult deformity

EULAR 2024 – Day 2 Report (A Difficult RA Day)

Jack Cush, MD

Day 2 at EULAR 2024 was a big poster day for many with several good sessions and oral presentations on Preventing RA, new vasculitis therapies and a session devoted to the 50th anniversary of the Moll & Wright Criteria.

Read Article
opposing point of view to previous post @RheumNow #EULAR2024 https://t.co/T72r8kXF1j

Links:

Peter Nash drpnash ( View Tweet)
Steroids are often started before pts see a rheumatologist This associates with long-term low-dose steroid use Need better collaboration between referrers and rheum to reduce this avoidable steroid burden POS0137 @RheumNow #EULAR2024

Mrinalini Dey DrMiniDey ( View Tweet)

« Glucocorticoids are such old drugs and we still use them so much » says Josef Smolen Summary slide from « 75th anniversary of GCd, what have we learnt? » @RheumNow #EULAR2024 https://t.co/XSRt44zupw

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
THE ASSOCIATION BETWEEN DEPRESSION AND BIOLOGIC PRESCRIBING IN AXIAL SPONDYLOARTHRITIS (axSpA): LESSONS FROM AN IRISH axSpA COHORT more likely to have peripheral arthritis enthesitis psoriasis - shoukd we be formally assessing eg Beck’s DI @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

Points to consider in pregnancy &lactation in Pts w #rheumatic #diseases #biologics don’t increase rate of serious infections in Mom Baby Compared to other matched pregnant and post partum women reassuring! #EULAR2024 @RheumNow @eular_org

Janet Pope Janetbirdope ( View Tweet)

What to use in men prior to planned conception of partner in #rheumatic #diseases #EULAR2024 ⁦@RheumNow⁩ ⁦@ACRheum⁩ ⁦@eular_org⁩ https://t.co/jMecV8jqUe

Links:

Janet Pope Janetbirdope ( View Tweet)
Points to consider in pregnancy in #rheumatic diseases 3 points ✅TNFi all OK 👍 ? Only if you can’t control disease use other #bDMARDs Baby #vaccinations if exposed to #biologics while present #rotovirus ok other live vaccines >6 mos #EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh

Links:

Janet Pope Janetbirdope ( View Tweet)
I think if we’re worried about JAK inhibitor safety, we need to be doing it right. I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read: https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg

Links:

David Liew drdavidliew ( View Tweet)

important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11

Links:

Peter Nash drpnash ( View Tweet)
#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RA patients on abatacept have an appalling immunogenic response to Shingrix. Humoral fades away in the first year, and an absence of cellular responses. Alarming and need strategies to combat this #EULAR2024 POS0620 Winthrop/@RADoctor @RheumNow https://t.co/8gY9ocLBDp

Links:

David Liew drdavidliew ( View Tweet)
#EULAR2024 POS0390 What impact of regulatory warning on JAK-i on access to therapy? Data from UK BSSR-BR reported 4 in 5 #RA patients would have been considered ‘high-risk’. Of these, 28% had failed ≥3 biologics; so no suitable alternatives. Enormously impacted @RheumNow https://t.co/XeS9qHXSpH

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Approach to TB screening prior to commencing biologics. Hyrich K #EULAR2024 @RheumNow https://t.co/j3PI0PHpqW

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
The art of talking about risks with our patients https://t.co/V0JQ1EsbKc https://t.co/GSTbPu0EXZ

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 Please find our Day 1 & Day 2 Recap of selective abstracts/research presented at the conference 😃@RheumNow @DrMiniDey https://t.co/AHl18gS7gF https://t.co/LEoa9rBNly

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The fracture risk with glucocorticoids is dose dependent. Lems W #EULAR2024 @RheumNow https://t.co/TGjKu1vfXx

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×